The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Kick-starting the cancer-immunity cycle by targeting CD40

På svenska

Author

  • Peter Ellmark
  • S. M. Mangsbo
  • C. Furebring
  • T. H. Totterman
  • P. Norlen

Summary, in English

Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.

Publishing year

2015

Language

English

Pages

1011484-1011484

Publication/Series

OncoImmunology

Volume

4

Issue

7

Document type

Journal article (comment)

Publisher

Landes Bioscience

Topic

  • Immunology in the medical area

Keywords

  • CD40
  • PD-1
  • agonistic antibody
  • immunooncology

Status

Published

ISBN/ISSN/Other

  • ISSN: 2162-4011